Major depressive disorder miRNA Postmortem brain Stress As a class of noncoding RNAs, microRNAs (miRNAs) regulate gene expression by inhibiting translation of messenger RNAs. These miRNAs have been shown to play a critical role in higher brain functioning and actively participate in synaptic plasticity. Pre-clinical evidence demonstrates that expression of miRNAs is differentially altered during stress. On the other hand, depressed individuals show marked changes in miRNA expression in brain. MiRNAs are also target of antidepressants and electroconvulsive therapy. Moreover, these miRNAs are present in circulating blood and can be easily detected. Profiling of miRNAs in blood plasma/serum provides evidence that determination of miRNAs in blood can be used as possible diagnostic and therapeutic tool. In this review article, these aspects are critically reviewed and the role of miRNAs in possible etiopathogenesis and therapeutic implications in the context of major depressive disorder is discussed.
Introduction
Major depressive disorder (MDD) is a common debilitating disorder with lifetime prevalence of more than 10% (Belmaker and Agam, 2008; Bromet et al., 2011) . About 50% patients suffering from MDD show suicidal thought and tendency at some point in their lives; of them 10-15% eventually commit suicide (Möller, 2003) . Interestingly, almost 50% of patients do not recover following an antidepressant trial and 20% of these patients fail to respond to any intervention (Labermaier et al., 2013; Warden et al., 2007) . This is partially a result of poor understanding of the molecular pathophysiology underlying MDD.
It is becoming increasingly evident that MDD may be associated with altered structural and synaptic plasticity, stress-related pathology, and to a certain extent, genetic polymorphism (Leistedt and Linkowski, 2013; Marsden, 2013; Ota and Duman, 2013) . Disruptions across whole cellular networks and aberrant information processing in the circuits that regulate mood and cognition may lead to altered synaptic and structural plasticity and may be crucial in the development of MDD. In this context, microRNAs (miRNAs), a prominent class of small noncoding RNAs, have gained prominent attention for their role in neural plasticity and higher brain functioning and their possible role in neurodegenerative disorders as well as psychiatric illnesses. (Dwivedi, 2011; Garza-Manero et al., 2014; Hommers et al., 2015; Im and Kenny, 2012) . By modulating translation and/or stability of a large number of mRNA targets in a coordinated and cohesive fashion, miRNAs have the capability to modulate disease phenotypes (Lages et al., 2012) .
The miRNAs are encoded within primary miRNA gene transcripts (Bartel, 2009; Bushati and Cohen, 2007) . The primary miRNAs are transcribed by RNA polymerase II, which are then processed by Class 2 RNase III enzyme Drosha along with other co-factors to form one or a series of small hairpin miRNA precursors, known as precursor-miRNAs. These precursor miRNAs are~70-110 nucleotides (nt) in length and fold into a stem-loop structure. The precursor-miRNAs are further processed in cytoplasm after being transported out of nucleus with the help of transportin 5 in conjunction with RanGTP. The stem loop structure is further processed by enzyme Dicer to form a double-stranded small RNAs about 22 nt. long. Generally, one of these strands is incorporated into a complex with one or more Argonaute homolog proteins (isoforms of eIF2c). The other strand is degraded (Krol et al., 2010) . Thus, singlestranded mature miRNA, together with eIF2c and other associated proteins such as fragile X mental retardation protein (FMRP), comprises the so-called RISC complex. The RISC complex binds to specific "short seed" sequences located predominantly within the 3'-untranslated region (UTR) region of mRNAs, and can interfere with translation of the mRNA and/or may reduce mRNA levels. In certain instances, miRNAs may activate translation or even act at the level of transcription by binding to specific gene promoters (Younger and Corey, 2011) .
Although miRNAs have been extensively studied in neurodegenerative disorders, the research on miRNAs in MDD and other psychiatric illnesses are still in infancy. The evidence of the role of miRNAs in MDD is primarily derived from preclinical studies demonstrating the role of miRNAs in synaptic plasticity and neurogenesis. The other piece of Progress in Neuro-Psychopharmacology & Biological Psychiatry 64 (2016) 341-348 Abbreviations: miRNA, microRNA; MDD, major depressive disorder; 3'UTR, 3' untranslated region; FMRP, fragile X mental retardation protein; DGCR8, DiGeorge Syndrome Critical Region Gene 8; PSD, postsynaptic density; RISC, RNA-induced silencing complex; LTD, long-term depression; LTP, long-term potentiation; Limk1, Lim kinase 1; SIRT, serotonin transporter; NR2A, NMDAR2A; APT1, acyl protein thioesterase 1; AChE, acetylcholinesterase; DR, dopamine receptor; 5HT, serotonin; GR, glucocorticoid receptor; GRM4, glutamate receptor-4; HTRIB, 5HT receptor 1B; SSRI, 5HT reuptake inhibitor.
E-mail address: ydwivedi@uab.edu. 
Contents lists available at ScienceDirect
Progress in Neuro-Psychopharmacology & Biological Psychiatry
